机构：[1]Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing 100142, China[2]Department of Gastrointestinal Surgery, Reiji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200127, China[3]Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China四川大学华西医院[4]Department of General Surgery, the General Hospital of the People’s Liberation Army, Beijing 100853, China[5]Department of Oncology, The Chinese People’s Liberation Army 81st Hospital, Nanjing 210031, Jiangsu Province, China[6]Department of Gastric Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China[7]Department of Gastrointestinal Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, Guangdong Province, China中山大学附属第一医院[8]Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing 320100, Jiangsu Province, China江苏省人民医院[9]Department of Hematology, Ren Ji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200240, China[10]Department of Respirology, Ren Ji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200240, China[11]Department of Dermatology, Ren Ji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200240, China[12]Department of Nephrology, The General Hospital of the People’s Liberation Army, Beijing 100853, China[13]Department of Endocrinology, The General Hospital of the People’s Liberation Army, Beijing 100853, China[14]Department of Ophthalmology, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China四川大学华西医院[15]Department of Oral and Maxillofacial Surgery, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, Sichuan Province, China
Tyrosine kinase inhibitors (TKIs) have improved the overall survival of patients with gastrointestinal stromal tumors (GISTs), but their side effects can impact dose intensity and, consequently, the clinical benefit. To date, no guideline or consensus has been published on the TKI-associated adverse reactions. Therefore, the Chinese Society of Surgeons for Gastrointestinal Stromal Tumor of the Chinese Medical Doctor Association organized an expert panel discussion involving representatives from gastrointestinal surgery, medical oncology, cardiology, dermatology, nephrology, endocrinology, and ophthalmology to consider the systemic clinical symptoms, molecular and cellular mechanisms, and treatment recommendations of GISTs. Here, we present the resultant evidence- and experience-based consensus to guide the management of TKI-associated side events in clinical practice.
第一作者机构：[1]Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing 100142, China
通讯作者：
通讯机构：[2]Department of Gastrointestinal Surgery, Reiji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200127, China[*1]Department of General Surgery, Renji Hospital, Shanghai Jiaotong University School of Medicine, No. 160, Pujian Road, Pudong New District, Shanghai 200127, China
推荐引用方式(GB/T 7714)：
Jian Li,Ming Wang,Bo Zhang,et al.Chinese consensus on management of tyrosine kinase inhibitor-associated side effects in gastrointestinal stromal tumors.[J].WORLD JOURNAL OF GASTROENTEROLOGY.2018,24(46):5189-5202.doi:10.3748/wjg.v24.i46.5189.
APA：
Jian Li,Ming Wang,Bo Zhang,Xin Wu,Tian-Long Lin...&Chinese Society of Surgeons for Gastrointestinal Stromal Tumor of the Chinese Medical Doctor Association.(2018).Chinese consensus on management of tyrosine kinase inhibitor-associated side effects in gastrointestinal stromal tumors..WORLD JOURNAL OF GASTROENTEROLOGY,24,(46)
MLA：
Jian Li,et al."Chinese consensus on management of tyrosine kinase inhibitor-associated side effects in gastrointestinal stromal tumors.".WORLD JOURNAL OF GASTROENTEROLOGY 24..46(2018):5189-5202
